The United States Geological Survey study detected one or more pharmaceuticals in 59 streams throughout the Southeast United States.
According to a new study published on May 24, 2016 from the US Geological Survey (USGS), pharmaceuticals are widespread in small streams across the Southeast United States. The study details how in 2014, the USGS sampled 59 small streams in portions of Alabama, Georgia, North Carolina, South Carolina, and Virginia for 108 different pharmaceutical compounds and detected one or more pharmaceuticals in all 59 streams. Results determined the average number of pharmaceuticals detected in the streams was six.
Previous research indicated that wastewater treatment facility discharges were the most likely source for pharmaceutical chemicals in surface water. However, the findings in this study, reported in the journal Environmental Science and Technology Letters, indicate the pharmaceuticals may originate from other sources as well-only 17 of the 59 streams have any reported wastewater discharges.
In a press announcement, USGS indicated the most common pharmaceutical chemicals detected are:
Although much uncertainty remains as to how pharmaceuticals affect aquatic organisms, some adverse effects have been documented. Antibiotic/antibacterial contaminants-detected in at least 20% of streams-can affect aquatic microbial communities, altering the base of the food web. Antihistamines, frequently detected in this study, affect neurotransmitters for many aquatic insects. And metformin, nearly ubiquitous in the streams studied, can affect the reproductive health of fish.
While the research indicated there were chemicals present in the water, none of them exceeded human health benchmarks. In addition to the individual chemicals listed, the two groups of compounds most frequently detected were nicotine-related compounds (71% of samples) and caffeine-related compounds (detected in 49% of samples).
Source: USGS
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.